Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

First-Ever CAR T-cell Therapy Approved in U.S.

9 Sept 2017

Abstract excerpt

The first chimeric antigen receptor T-cell therapy, tisagenlecleucel, received FDA approval for the treatment of patients up to 25 years of age with B-cell precursor acute lymphoblastic leukemia who haven't responded to standard therapy or who have relapsed at least twice.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomedical Ethics and Regulation
Share to CAR-T cell therapy research
Share to Science, Research, and Medicine

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 28887358
DOI: 10.1158/2159-8290.cd-nb2017-126

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

First-Ever CAR T-cell Therapy Approved in U.S.PMID 28887358Read ↗

CAR-T Cell TherapySemantic proximity Read ↗

Chimeric Antigen Receptor‐T Cell TherapySemantic proximity Read ↗

CAR-T-Cell Therapy: Present Progress and Future strategiesSemantic proximity Read ↗

The progress of CAR-T therapy in cancer and beyondSemantic proximity Read ↗

The rules of T-cell engagement: current state of CAR T cells and bispecific antibodies in B-cell lymphomasSemantic proximity Read ↗

Next-Generation Chimeric Antigen Receptor T-cellsSemantic proximity Read ↗

Chimeric Antigen Receptor Based Cellular Therapy for Treatment Of T-Cell MalignanciesSemantic proximity Read ↗

The FDA’s Regulatory Framework for Chimeric Antigen Receptor‐T Cell TherapiesSemantic proximity Read ↗

The Fate(s) of CAR T-Cell Therapy: Navigating the Risks of CAR+ T-Cell MalignancySemantic proximity Read ↗

First generation anti-CD19 chimeric antigen receptor-modified T cells for management of B cell malignances: initial analysis of an ongoing Phase I clinical trialSemantic proximity Read ↗

Chimeric Antigen Receptor T-Cell Therapy: What We Expect SoonSemantic proximity Read ↗

T-Cell Cancer after CAR T-Cell TherapySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.